Clinical Trial Results - Moderna 的 mRNA 流感疫苗候选产品在后期试验中显示出积极结果 [1] Stock Market Performance - Moderna 的股票在试验结果公布后上涨 [1]

A broad variety of programs These programs also span many indications, from cytomegalovirus to oncology -- this is positive because Moderna won't depend on just one or two treatment areas in the future, reducing risk if one product sees a slowdown. It's also important to note that there's less risk of a slowdown when treating an ever-present virus or disease versus dealing with a pandemic situation -- pandemics result in steep gains, but when the situation improves, sales may sharply drop off. Moderna's suc ...